No disrespect to anyone but I'm not sure going down memory lane...

No disrespect to anyone but I'm not sure going down memory lane is relevant to current

Immutep direction......CVAC in no uncertain terms showed promise and results but

the cold hard facts are it was too involved to interest modern pharma, borne out by

primas inability to offload to anyone but someone who has been unable to interest

anyone in making an offer...

Let's arrive at the here and now, Prima of 2014 upon the acquisition of ImmutepSA

and the abandonment of CVAC managed to convince Ridgeback to invest $15M

and to this day they still hold....

I note.....Edisons valued IMM at 17c recently, adjusted down to 12c if Ridgeback's

options, notes, warrants are exercised.....

As macca says, AIPAC is the key, basically in about 9 months we'll know if it is

good,half good or no good.....There lies the success or failure of immutep IMO....

Shares on issue have increased but in that regard targeted market value has

increased far more.....

We are mixed up in the high end of the I/O landscape and in an advantageous

position at this point in time in regard to potential, interest from others is strong

and backed up by a strong management, if "efti" comes good for us the shares

on issue will be inconseqentional IMO.....The biotech community understands

the share register will rise until income can be produced, it's the way of funding

without selling the farm off in bits and pieces.....

The future is looking bright, the past doesn't matter...